3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
6
Hematologic Neoplasms
2
Waldenstrom Macroglobulinemia
1
Mature B-cell Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, B-Cell
1
Interventions
Cyclophosphamide
28
Rituximab
23
fludarabine
14
fludarabine phosphate
12
Specimen Handling
11
obinutuzumab
10
ibrutinib
10
Magnetic Resonance Spectroscopy
10
Prednisone
8
Doxorubicin
8
tocilizumab
7
polatuzumab vedotin
7
X-Rays
7
Whole-Body Irradiation
7
Phantoms, Imaging
7
Mycophenolic Acid
7
Etoposide
7
Biopsy
7
venetoclax
6
glofitamab
6
Melphalan
6
Lenalidomide
6
Bendamustine Hydrochloride
6
pirtobrutinib
5
acalabrutinib
5
Vincristine
5
Peripheral Blood Stem Cell Transplantation
5
Nuclear Medicine Department, Hospital
5
Nivolumab
5
Gemcitabine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
ARQ531
×
90 days
×
Clear all
NCT04728893
2026-05-26
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2
Recruiting
490 enrolled